Exelixis
EXEL
#1637
Rank
NZ$17.90 B
Marketcap
$63.98
Share price
-0.38%
Change (1 day)
61.08%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.47

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.49. In 2022 the company made an earnings per share (EPS) of $0.99 a decrease over its 2021 EPS that were of $1.29.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.47-52.98%
2022$0.99-22.97%
2021$1.29100%
2020$0.65-65.09%
2019$1.85-53.91%
2018$4.01333.96%
2017$0.92-260.61%
2016-$0.58-58.75%
2015-$1.39-42.45%
2014-$2.425.3%
2013-$2.3043.48%
2012-$1.60-264.29%
2011$0.98-165.88%
2010-$1.48-32.54%
2009-$2.20-17.65%
2008-$2.6775.86%
2007-$1.52-25.64%
2006-$2.048.33%
2005-$1.88-42.86%
2004-$3.2930.34%
2003-$2.53-5.23%
2002-$2.67-0.65%
2001-$2.68-51.88%
2000-$5.58

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$6.10 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.54 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$3.18 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.92 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.67 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$24.55 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.24 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$17.43-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.46-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA